Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial

BACKGROUND: COVID-19 is associated with acute respiratory distress and cytokine release syndrome. The Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib reduces inflammatory cytokine concentrations in disorders characterised by cytokine dysregulation, including graft-versus-host disease, myelofibrosis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, MeiLan K, Antila, Martti, Ficker, Joachim H, Gordeev, Ivan, Guerreros, Alfredo, Bernus, Amparo Lopez, Roquilly, Antoine, Sifuentes-Osornio, José, Tabak, Fehmi, Teijeiro, Ricardo, Bandelli, Lorraine, Bonagura, Diane S, Shu, Xu, Felser, James M, Knorr, Barbara, Cao, Weihua, Langmuir, Peter, Lehmann, Thomas, Levine, Michael, Savic, Sinisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963773/
https://www.ncbi.nlm.nih.gov/pubmed/35368384
http://dx.doi.org/10.1016/S2665-9913(22)00044-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963773/
https://www.ncbi.nlm.nih.gov/pubmed/35368384
http://dx.doi.org/10.1016/S2665-9913(22)00044-3

Ejemplares similares